COVID Has Led to Big Declines in Cancer Screenings, New Diagnoses COVID Has Led to Big Declines in Cancer Screenings, New Diagnoses
The large study helps quantify the extent to which the pandemic has affected new diagnoses of prostate, lung, bladder, and colorectal cancers in 2020.Medscape Medical News (Source: Medscape Pulmonary Medicine Headlines)
Source: Medscape Pulmonary Medicine Headlines - December 6, 2021 Category: Respiratory Medicine Tags: Hematology-Oncology News Source Type: news
300 Minutes a Week of Moderate Exercise May Help Ward Off Cancer
More than 46,000 cancers in America each year, or about 3 percent of cases, could be prevented by meeting physical activity guidelines. (Source: NYT Health)
Source: NYT Health - November 17, 2021 Category: Consumer Health News Authors: Gretchen Reynolds Tags: Exercise Bladder Cancer Colon and Colorectal Cancer Stomach Cancer Breast Cancer Smoking and Tobacco American Cancer Society Medicine & Science in Sports Exercise (Journal) Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
3 Percent of U.S. Cancer Cases Attributable to Physical Inactivity
Population - attributable fraction varied from 3.9 percent for urinary bladder cancer to 16.9 percent for stomach cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 22, 2021 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Gynecology, Internal Medicine, Nephrology, Oncology, Pulmonology, Urology, Journal, Source Type: news
Clinical Trial Design for Non-Muscle Invasive Bladder Cancer (NMIBC) - 11/18/2021 - 11/19/2021
The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) and Center for Drug Evaluation and Research (CDER) welcome you to this FDA Virtual Public Workshop: Clinical Trial Design for Non-Muscle Invasive Bladder Cancer (NMIBC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 7, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Avelumab cost effective for advanced urothelial bladder cancer?
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2021 Category: Drugs & Pharmacology Source Type: news
Two tablet a day treatment that can stop bladder cancer for 18 months
Professor Thomas Powels, pictured, oncologist and director of the Barts Cancer Centre where the trial took place said those given the two-pronged treatment will 'undoubtedly live for longer'. (Source: the Mail online | Health)
Source: the Mail online | Health - September 18, 2021 Category: Consumer Health News Source Type: news
Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral presentation at t...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
DR ELLIE CANNON: I can't stop worrying that cancer runs in my family - and I'll be next
Cancer isn't one disease, it's many. So, for example, the causes and characteristics of bladder cancer are quite distinct and not connected to those of stomach cancer or other cancers, says DR ELLIE. (Source: the Mail online | Health)
Source: the Mail online | Health - September 4, 2021 Category: Consumer Health News Source Type: news
Accelerated Approval Now Full for Pembro in Bladder Cancer Accelerated Approval Now Full for Pembro in Bladder Cancer
A controversial accelerated approval of this immunotherapy, based on response data, has now been converted to a full approval by the FDA.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
What Are the First Signs of Bladder Cancer
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - August 31, 2021 Category: General Medicine Source Type: news
Researchers Study New Immunotherapy Combination for Mesothelioma
The immunotherapy combination of tremelimumab and durvalumab has shown surprising efficacy, particularly as a second-line treatment option for patients with pleural mesothelioma, according to a recent study.
Its effectiveness, comparable to a similar combination which was approved in 2020 by the U.S. Food and Drug Administration, further illustrated the new direction for future treatment of mesothelioma.
Chemotherapy will no longer be the stand-alone, standard-of-care treatment for most patients.
“Promising results have emerged on the use of targeted treatment with immune checkpoint inhibitors (ICI), particularl...
Source: Asbestos and Mesothelioma News - August 30, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news
